Novel inhibitors

A solvate, selected technology, applied in the directions of medical preparations containing active ingredients, allergic diseases, drug combinations, etc., can solve the problem of not showing sequence homology and the like

Active Publication Date: 2020-01-21
VIVORYON THERAPEUTICS NV
View PDF640 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, comparison of the primary structure of the QC from papaya with that of the highly conserved QC

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel inhibitors
  • Novel inhibitors
  • Novel inhibitors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0960] In another embodiment, the present invention provides compounds of formula (IIa) and (IIb), wherein X 1 , n, Z, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , R 5 and R 6 As defined in Examples 1 to 265:

[0961]

[0962]

[0963]

[0964]

[0965]

[0966]

[0967]

[0968]

[0969] In another embodiment, the present invention provides compounds of formula (IIIa) and (IIIb), wherein X 1 , n, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , R 5 and R 6 As defined in Examples 266 to 443:

[0970]

[0971]

[0972]

[0973]

[0974]

[0975]

[0976] In another embodiment, the present invention provides compounds of formula (IVa) and (IVb), wherein X 1 , o, Z, Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , Y 6 , Y 7 , Y 8 , Y 9 , Y 10 , R 5 and R 6 As defined in Examples 444 to 795:

[0977]

[0978] In both formulas (IVa) and (IVb), o is 0.

[0979]

[0980]

[0981]

[...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a compound of formula (I): A-B-D-E (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein: A is selected from monocyclic and bicyclic heteroaryl, which may independently substituted by alkyl or amino; B is selected from alkyl, heteroalkyl, alkyl-amino, aryl, heteroaryl, cycloalkyl, heterocyclyl and alkylene, wherein said groups may independently be substituted by alkyl; D is selected from aryl-amino, heteroaryl-amino, cycloalkyl-amino, heterocyclyl, heterocyclyl-amino, urea, thioamide, thiourea, sulfonamide, sulfoximine and sulfamoyl, wherein said aryl, heteroaryl, cycloalkyl and heterocyclyl groups may independently be substituted; and E is selected from aryl, heteroaryl, cycloalkyl, heterocyclyl, wherein said aryl, heteroaryl, cycloalkyl and heterocyclyl groups may independently be substituted. The compounds of formula (I) are inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.

Description

technical field [0001] The present invention relates to novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues to pyroglutamic acid (5-oxo-prolyl, pGlu*) upon release of ammonia, and the N-terminal glutamic acid residues upon release of water. Intramolecular cyclization to pyroglutamic acid. Background technique [0002] Glutaminyl cyclase (QC, EC 2.3.2.5) catalyzes the intramolecular cyclization of N-terminal glutamine residues to pyroglutamate (pGlu*), releasing ammonia. QC was first isolated from the latex of the tropical plant Carica papaya by Messer in 1963 (Messer, M.1963 Nature 4874, 1299). After 24 years, a corresponding enzymatic activity was found in animal pituitary glands (Busby, W.H.J. et al. 1987 J Biol Chem 262, 8532-8536; Fischer, W.H. and Spiess, J. 1987 Proc Natl Acad Sci USA 84, 3628-3632). For mammalian QC, the conversion of Gln to pGlu by QC can ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D403/12C07D401/12C07D401/04C07D235/06C07D417/04C07D417/12C07D249/08C07D285/135A61P25/00A61P35/00A61P37/00
CPCA61P25/00A61P35/00A61P37/00C07D235/06C07D249/08C07D285/135C07D401/04C07D401/12C07D403/12C07D417/04C07D417/12C07B2200/13C07D235/08C07D277/40A61K45/06C07D249/14A61K31/433A61K31/4196A61K31/428A61K31/437A61K31/497A61K31/506
Inventor U·海泽T·霍夫曼I·卢埃斯A·迈尔
Owner VIVORYON THERAPEUTICS NV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products